Applications of metabolomics in cancer research

The first discovery of metabolic changes in cancer occurred almost a century ago. While the genetic underpinnings of cancer have dominated its study since then, altered metabolism has recently been acknowledged as a key hallmark of cancer and metabolism-focused research has received renewed attention. The emerging field of metabolomics – which attempts to profile all metabolites within a cell or biological system – is now being used to analyze cancer metabolism on a system-wide scale, painting a broad picture of the altered pathways and their interactions with each other. While a large fraction of cancer metabolomics research is focused on finding diagnostic biomarkers, metabolomics is also being used to obtain more fundamental mechanistic insight into cancer and carcinogenesis. Applications of metabolomics are also emerging in areas such as tumor staging and assessment of treatment efficacy. This review summarizes contributions that metabolomics has made in cancer research and presents the current challenges and potential future directions within the field.

[1]  E. Mikros,et al.  (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool. , 2010, Journal of proteome research.

[2]  Royston Goodacre,et al.  Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. , 2011, Chemical Society reviews.

[3]  P. West,et al.  Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. , 2010, Toxicology and applied pharmacology.

[4]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[5]  Daniel Raftery,et al.  Early detection of recurrent breast cancer using metabolite profiling. , 2010, Cancer research.

[6]  Ivano Bertini,et al.  Evidence of different metabolic phenotypes in humans , 2008, Proceedings of the National Academy of Sciences.

[7]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[8]  R. Weiss,et al.  Urinary acylcarnitines are altered in human kidney cancer , 2012, International Journal of Cancer.

[9]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[10]  S. Choi,et al.  An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis. , 2012, Cancer research.

[11]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[12]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[13]  M. Arbushites,et al.  Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study , 2012, Molecular oncology.

[14]  John C Lindon,et al.  Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism , 2009, Proceedings of the National Academy of Sciences.

[15]  Pär Stattin,et al.  Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of Cholesterol , 2010, PloS one.

[16]  Shih-Chieh Lin,et al.  Induction of Pyruvate Dehydrogenase Kinase-3 by Hypoxia-inducible Factor-1 Promotes Metabolic Switch and Drug Resistance* , 2008, Journal of Biological Chemistry.

[17]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[18]  Chi V Dang,et al.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. , 2010, Cancer research.

[19]  Jin-lian Chen,et al.  Prediction of gastric cancer metastasis through urinary metabolomic investigation using GC/MS. , 2011, World journal of gastroenterology.

[20]  Yusuke Nakamura,et al.  Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics , 2012, Pharmacogenetics and genomics.

[21]  J R Griffiths,et al.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. , 2005, Human molecular genetics.

[22]  Oliver Fiehn,et al.  Seven Golden Rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry , 2007, BMC Bioinformatics.

[23]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[24]  Yiran Huang,et al.  Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. , 2008, Analytica chimica acta.

[25]  John C Lindon,et al.  Pharmacometabonomics as an effector for personalized medicine. , 2011, Pharmacogenomics.

[26]  G. Kristiansen,et al.  Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. , 2010, European urology.

[27]  A. Cebrián,et al.  Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics , 2011, Clinical and Translational Oncology.

[28]  Oliver Fiehn,et al.  A comprehensive urinary metabolomic approach for identifying kidney cancerr. , 2007, Analytical biochemistry.

[29]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[30]  W. Dunn,et al.  Measuring the metabolome: current analytical technologies. , 2005, The Analyst.

[31]  Yong Yue,et al.  Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. , 2007, Journal of proteome research.

[32]  A. Darzi,et al.  1H HR-MAS NMR spectroscopy of tumor-induced local metabolic "field-effects" enables colorectal cancer staging and prognostication. , 2013, Journal of proteome research.

[33]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[34]  Elaine Holmes,et al.  High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues , 2010, Nature Protocols.

[35]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[36]  E. Fukusaki,et al.  Serum metabolomics as a novel diagnostic approach for pancreatic cancer , 2010, Metabolomics.

[37]  O. Slanař,et al.  Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation. , 2009, Journal of proteome research.

[38]  Alan Hutson,et al.  Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.

[39]  Jason W. Locasale,et al.  Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells , 2010, Science.

[40]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[41]  David S. Wishart,et al.  HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..

[42]  Thomas M O'Connell,et al.  Recent advances in metabolomics in oncology. , 2012, Bioanalysis.

[43]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[44]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[45]  Tao-Tao Liu,et al.  A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. , 2008, Rapid communications in mass spectrometry : RCM.

[46]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[47]  H. Thomas,et al.  Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. , 2011, Journal of proteome research.

[48]  Edoardo Saccenti,et al.  Individual human phenotypes in metabolic space and time. , 2009, Journal of proteome research.

[49]  Z. Bhujwalla,et al.  Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.

[50]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[51]  Shuying Liu,et al.  A METABONOMICS STUDY OF COLORECTAL CANCER BY RRLC-QTOF/MS , 2012 .

[52]  Tianlu Chen,et al.  Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. , 2009, Journal of proteome research.

[53]  O. Fiehn,et al.  Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. , 2006, Cancer research.

[54]  Ping Liu,et al.  Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma* , 2011, Molecular & Cellular Proteomics.

[55]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[56]  Xiaomei Yan,et al.  Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. , 2010, The Analyst.

[57]  O. Fiehn Metabolomics – the link between genotypes and phenotypes , 2004, Plant Molecular Biology.

[58]  Xiaomei Yan,et al.  LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. , 2011, Journal of proteome research.

[59]  Daniel K Nomura,et al.  Global profiling strategies for mapping dysregulated metabolic pathways in cancer. , 2012, Cell metabolism.

[60]  Qing Yang,et al.  Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[61]  Alexander G. Gray,et al.  Rapid Mass Spectrometric Metabolic Profiling of Blood Sera Detects Ovarian Cancer with High Accuracy , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[62]  Reinhard Laubenbacher,et al.  Bioinformatics tools for cancer metabolomics , 2011, Metabolomics.

[63]  Liping Zhao,et al.  Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. , 2007, Journal of proteome research.

[64]  Hui Sun,et al.  Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[65]  L. Tenori,et al.  Targeting Metabolomics in Breast Cancer , 2012, Current Breast Cancer Reports.

[66]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[67]  S. Clarke,et al.  Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine , 2011, Clinical Cancer Research.

[68]  Claudio Luchinat,et al.  Uncovering the metabolomic fingerprint of breast cancer. , 2011, The international journal of biochemistry & cell biology.

[69]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[70]  T. Takenawa,et al.  A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer , 2012, PloS one.

[71]  Xin Lu,et al.  Metabolomic Changes Accompanying Transformation and Acquisition of Metastatic Potential in a Syngeneic Mouse Mammary Tumor Model* , 2010, The Journal of Biological Chemistry.

[72]  Timothy M. D. Ebbels,et al.  Consensus-Phenotype Integration of Transcriptomic and Metabolomic Data Implies a Role for Metabolism in the Chemosensitivity of Tumour Cells , 2011, PLoS Comput. Biol..

[73]  Yiran Huang,et al.  Application of ex vivo 1H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases , 2012, Journal of Cancer Research and Clinical Oncology.

[74]  Z. Bhujwalla,et al.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. , 1999, Cancer research.

[75]  Hui Cong,et al.  Application of 1H NMR‐based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis , 2009, Cancer science.

[76]  G. Semenza HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[77]  Bowei Xi,et al.  Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. , 2011, Analytica chimica acta.

[78]  David Beach,et al.  Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.

[79]  W. Kaelin Faculty Opinions recommendation of Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. , 2008 .

[80]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[81]  A. M. Gil,et al.  Metabolic signatures of cancer unveiled by NMR spectroscopy of human biofluids. , 2012, Progress in nuclear magnetic resonance spectroscopy.

[82]  Xi-jun Wang,et al.  Modern analytical techniques in metabolomics analysis. , 2012, The Analyst.

[83]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[84]  R. Weiss,et al.  Urine metabolomics for kidney cancer detection and biomarker discovery. , 2011, Urologic oncology.

[85]  R. Deberardinis,et al.  Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. , 2012, Cell metabolism.

[86]  Tao Zhang,et al.  Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. , 2013, Journal of proteome research.

[87]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[88]  Flavio Rizzolio,et al.  Pharmaco‐metabolomics: An emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets , 2012, Journal of cellular physiology.

[89]  Joachim Selbig,et al.  Metabolic profiling reveals key metabolic features of renal cell carcinoma , 2009, Journal of cellular and molecular medicine.

[90]  O. Fiehn,et al.  FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. , 2009, Analytical chemistry.

[91]  R. Weiss,et al.  Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. , 2011, Omics : a journal of integrative biology.

[92]  John Kurhanewicz,et al.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.

[93]  A. Mancuso,et al.  p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase , 2011, Nature Cell Biology.

[94]  H. Degani,et al.  Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. , 2002, Cancer research.

[95]  Tianlu Chen,et al.  Urinary metabonomic study on colorectal cancer. , 2010, Journal of proteome research.

[96]  Kyoungmi Kim,et al.  Urine Metabolomics Analysis for Kidney Cancer Detection and Biomarker Discovery*S , 2009, Molecular & Cellular Proteomics.

[97]  Rachel Cavill,et al.  Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). , 2009, Journal of proteome research.

[98]  Ivano Bertini,et al.  Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. , 2012, Cancer research.

[99]  Theodoros N. Arvanitis,et al.  Birmingham Metabolite Library: a publicly accessible database of 1-D 1H and 2-D 1H J-resolved NMR spectra of authentic metabolite standards (BML-NMR) , 2011, Metabolomics.

[100]  P. Morris,et al.  Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[101]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[102]  Joachim Selbig,et al.  The Golm Metabolome Database: a database for GC-MS based metabolite profiling , 2007 .

[103]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[104]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[105]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[106]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[107]  T. Sørlie,et al.  Merging transcriptomics and metabolomics - advances in breast cancer profiling , 2010, BMC Cancer.

[108]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[109]  J. Dufour,et al.  Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. , 2011, Cancer research.

[110]  W. Moon,et al.  An HR-MAS MR Metabolomics Study on Breast Tissues Obtained with Core Needle Biopsy , 2011, PloS one.

[111]  M. Sawyer,et al.  Urine Metabolite Analysis Offers Potential Early Diagnosis of Ovarian and Breast Cancers , 2010, Clinical Cancer Research.

[112]  E. Negelein,et al.  THE METABOLISM OF CARCINOMA CELLS , 2011 .